- Home
- CCG vs ESLA Comparison
CCG vs ESLA Comparison
Compare CCG & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCG | ESLA |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 32.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCG | ESLA |
|---|---|---|
| Price | $15.96 | $0.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $350.00 | $8.00 |
| AVG Volume (30 Days) | 20.7K | ★ 27.4K |
| Earning Date | 05-27-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $567.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.59 |
| 52 Week High | $18.16 | $3.15 |
Technical Indicators
Market Signals| Indicator | CCG | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 40.28 |
| Support Level | $0.65 | N/A |
| Resistance Level | $16.17 | $0.85 |
| Average True Range (ATR) | 1.66 | 0.07 |
| MACD | -0.71 | -0.00 |
| Stochastic Oscillator | 17.95 | 45.24 |
Price Performance
Historical ComparisonAbout CCG Cheche Group Inc.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services, and other services in China. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.